Title
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients
Author
Korst, A.E.C.
van der Sterre, M.L.T.
Gall, H.E.
Fichtinger-Schepman, A.M.J.
Vermorken, J.B.
van der Vijgh, W.J.F.
Centraal Instituut voor Voedingsonderzoek TNO
Publication year
1998
Abstract
The pharmacokinetics of cisplatin was investigated in 13 patients receiving 18 courses of cisplatin alone or in combination with amifostine to investigate the influence of amifostine (WR 2721; Ethyol) on the pharmacokinetics of cisplatin. Cisplatin was administered as a 1-h i.v. infusion, whereas amifostine was given i.v. over 15 min just before the cisplatin infusion. An increase in the final half-life of ultrafilterable platinum was observed after treatment with cisplatin and amifostine (t( 1/4 ), 0.77 ± 0.10 h; n = 8), compared to cisplatin alone (t( 1/4 ), 0.57 ± 0.15 h; n = 8). This might be caused by an influence of amifostine on the kidney function, because an increase in the serum creatinine levels was also observed 24 h after treatment with cisplatin and amifostine (13.8 ± 12.6%; n = 9), which was not observed after treatment with cisplatin alone (-0.1 ± 6.8%; n = 9). Surprisingly, the final half-life of unchanged cisplatin did not increase, but even showed a slight decrease after treatment with amifostine. In vitro data would suggest that this might be due to a chemical interaction between cisplatin and amifostine. Because the AUC values of ultrafilterable platinum and unchanged cisplatin did not change significantly and no change in Pt-DNA adduct (Pt-GG) levels in leukocytes was observed upon addition of amifostine in the treatment schedule, the change in the pharmacokinetics of cisplatin is most probably of minor importance and has no significant impact on the efficacy of cisplatin, as already confirmed by clinical studies.
Subject
Nutrition
Amifostine
Cisplatin
Creatinine
Adult
Aged
Area under the curve
Clinical article
Creatinine blood level
Dna adduct
Dna drug complex
Drug blood level
Drug effect
Drug half life
Female
Human
Intravenous drug administration
Kidney function
Male
Malignant neoplastic disease
Priority journal
Amifostine
Antineoplastic Agents
Cisplatin
DNA Adducts
Drug Interactions
Female
Half-Life
Hemofiltration
Humans
Leukocytes
Male
Middle Aged
Neoplasms
Platinum
Radiation-Protective Agents
To reference this document use:
http://resolver.tudelft.nl/uuid:e845b3f6-004e-43df-88ef-dbd008cbcdf6
TNO identifier
234360
ISSN
1078-0432
Source
Clinical Cancer Research, 4 (2), 331-336
Document type
article